Patient preferences for key drivers and facilitators of adoption of mHealth technology to manage depression: A discrete choice experiment.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
15 06 2023
Historique:
received: 29 07 2022
revised: 10 03 2023
accepted: 12 03 2023
medline: 14 4 2023
pubmed: 20 3 2023
entrez: 19 3 2023
Statut: ppublish

Résumé

In time, we may be able to detect the early onset of symptoms of depression and even predict relapse using behavioural data gathered through mobile technologies. However, barriers to adoption exist and understanding the importance of these factors to users is vital to ensure maximum adoption. In a discrete choice experiment, people with a history of depression (N = 171) were asked to select their preferred technology from a series of vignettes containing four characteristics: privacy, clinical support, established benefit and device accuracy (i.e., ability to detect symptoms), with different levels. Mixed logit models were used to establish what was most likely to affect adoption. Sub-group analyses explored effects of age, gender, education, technology acceptance and familiarity, and nationality. Higher level of privacy, greater clinical support, increased perceived benefit and better device accuracy were important. Accuracy was the most important, with only modest compromises willing to be made to increase other factors such as privacy. Established benefit was the least valued of the attributes with participants happy with technology that had possible but unknown benefits. Preferences were moderated by technology acceptance, age, nationality, and educational background. For people with a history of depression, adoption of technology may be driven by the desire for accurate detection of symptoms. However, people with lower technology acceptance and educational attainment, those who were younger, and specific nationalities may be willing to compromise on some accuracy for more privacy and clinical support. These preferences should help shape design of mHealth tools.

Sections du résumé

BACKGROUND
In time, we may be able to detect the early onset of symptoms of depression and even predict relapse using behavioural data gathered through mobile technologies. However, barriers to adoption exist and understanding the importance of these factors to users is vital to ensure maximum adoption.
METHOD
In a discrete choice experiment, people with a history of depression (N = 171) were asked to select their preferred technology from a series of vignettes containing four characteristics: privacy, clinical support, established benefit and device accuracy (i.e., ability to detect symptoms), with different levels. Mixed logit models were used to establish what was most likely to affect adoption. Sub-group analyses explored effects of age, gender, education, technology acceptance and familiarity, and nationality.
RESULTS
Higher level of privacy, greater clinical support, increased perceived benefit and better device accuracy were important. Accuracy was the most important, with only modest compromises willing to be made to increase other factors such as privacy. Established benefit was the least valued of the attributes with participants happy with technology that had possible but unknown benefits. Preferences were moderated by technology acceptance, age, nationality, and educational background.
CONCLUSION
For people with a history of depression, adoption of technology may be driven by the desire for accurate detection of symptoms. However, people with lower technology acceptance and educational attainment, those who were younger, and specific nationalities may be willing to compromise on some accuracy for more privacy and clinical support. These preferences should help shape design of mHealth tools.

Identifiants

pubmed: 36934854
pii: S0165-0327(23)00364-6
doi: 10.1016/j.jad.2023.03.030
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

334-341

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Conflicts of interest None.

Auteurs

S K Simblett (SK)

Department of Psychology, King's College London, London, UK. Electronic address: sara.simblett@kcl.ac.uk.

M Pennington (M)

King's Health Economics, King's College London, London, UK.

M Quaife (M)

Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.

S Siddi (S)

Parc Sanitari Sant Joan de Déu, Fundación Sant Joan de Déu, Centro de Investigación Biomedica en Red (CIBER), Barcelona, Spain.

F Lombardini (F)

Parc Sanitari Sant Joan de Déu, Fundación Sant Joan de Déu, Centro de Investigación Biomedica en Red (CIBER), Barcelona, Spain.

J M Haro (JM)

Fundació Idiap Jordi Gol i Gurina, Barcelona, Spain.

M T Peñarrubia-Maria (MT)

Fundació Idiap Jordi Gol i Gurina, Barcelona, Spain.

S Bruce (S)

RADAR-CNS Patient Advisory Board, King's College London, UK.

R Nica (R)

RADAR-CNS Patient Advisory Board, King's College London, UK.

S Zorbas (S)

RADAR-CNS Patient Advisory Board, King's College London, UK.

A Polhemus (A)

Merck Research Labs IT, Merck Sharpe, & Dohme, Prague, Czech Republic; Human Genetics, Charles University, Faculty of Science, Prague, Czech Republic.

J Novak (J)

Merck Research Labs IT, Merck Sharpe, & Dohme, Prague, Czech Republic; Department of Anthropology and Human Genetics, Charles University, Faculty of Science, Prague, Czech Republic.

E Dawe-Lane (E)

Department of Psychology, King's College London, London, UK.

D Morris (D)

Department of Psychology, King's College London, London, UK.

M Mutepua (M)

Department of Psychology, King's College London, London, UK.

C Odoi (C)

Department of Psychology, King's College London, London, UK; Department of Anthropology and Human Genetics, Charles University, Faculty of Science, Prague, Czech Republic.

E Wilson (E)

Department of Psychology, King's College London, London, UK.

F Matcham (F)

Department of Psychological Medicine, King's College London, London, UK.

K M White (KM)

Department of Psychological Medicine, King's College London, London, UK.

M Hotopf (M)

NIHR South London and Maudsley Biomedical Research Centre, London, UK; Department of Psychological Medicine, King's College London, London, UK.

T Wykes (T)

Department of Psychology, King's College London, London, UK; NIHR South London and Maudsley Biomedical Research Centre, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH